ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Evaluation of JQ1 Combined With Docetaxel for the Treatment of Prostate Cancer Cells in 2D-and 3D-Culture Systems

Xu, Yipeng; Pachnikova, Gabriela; Przybilla, Dorothea; Schafer, Reinhold; Cui, Yingying; Zhou, Dan; Chen, Zihao; Zhao, An*; Keilholz, Ulrich*南方医科大学; 中国科学院研究生院; 中国科学院
Frontiers in Pharmacology2022-2-3DOI: 10.3389/fphar.2022.839620
6被引16阅读
引用收藏
分享

摘要

Introduction: Prostate cancer (PCa) is dependent on coupled androgen-androgen receptor (AR) signaling for growth and progression. Significant efforts have been made in this research field, as hormonal therapies have greatly improved the survival of patients with metastatic PCa (mPCa). The drug treatment agent JQ1, which potently abrogates bromodomain 4 (BRD4) localization to the AR target loci and therefore significantly impairs AR-mediated gene transcription, is a potent therapeutic option for patients with advanced PCa. In this study, we aimed to investigate the inhibitory effect of JQ1 combined with docetaxel on PCa cells in vitro for the first time. Furthermore, the 3D spheroid culture system was modeled to more accurately simulate the response of PCa cells to drugs.Methods: We established and measured 3D LNCaP spheroids in vitro in order to evaluate the susceptibility of 2D- and 3D-cultured LNCaP cells exposed to the same anti-cancer drug.Results: We demonstrated that JQ1 was an effective drug for promoting cell inhibition after docetaxel treatment in 2D- and 3D- cultured LNCaP cells. Inhibition of 3D cultured formation in the combined treatment group was significantly higher than that in docetaxel or JQ1 alone. Under the same conditions of drug solubility, the drug resistance of 3D spheroids was significantly higher than that of 2D cells. Moreover, d(max) and lg volume were suitable parameters for LNCaP cells/spheroid size displaying and evaluating cell viability.Conclusion: 3D cultured spheroids of PCa are an effective tool for studying PCa drug trials. JQ1 combined with docetaxel may be an effective treatment for advanced PCa. This combination therapy strategy deserves further evaluation in clinical trials.

学科与关键词

关键词
Prostate CancerJQ1DocetaxelCombination Treatment3D Culture Spheroid
相关
加载中…
  • IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation
    Xu, Yipeng; Pachnikova, Gabriela; Wang, He; Wu, Yaoyao; Przybilla, Dorothea; Schaefer, Reinhold; Chen, Zihao; Zhu, Shaoxing*; Keilholz, Ulrich*Bosnian Journal of Basic Medical Sciences, 2022, 22(4): 580-592.被引 4
  • Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
    Chen, Ming-kun; Liang, Zhi-jian; Luo, Dao-Sheng; Xue, Kang-yi; Liao, De-ying; Li, Zheshen; Yu, Yuzhong; Chen, Zhe-Sheng*; Zhao, Shan-Chao*Frontiers in Pharmacology, 2022, 13: 843110.被引 4
  • IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
    Zhang, Yifan; Liao, Yuanpeng; Luo, Mayao; Ye, Yuedian; Xu, Zhuofan; Hou, Wenli; Liu, Ruiyu; Zhai, Qiliang; Lv, Shidong*; Wei, Qiang*PROSTATE, 2023, 83(15): 1446-1457.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2022-02-03
卷期
第 13 卷
页码
839620
DOI
10.3389/fphar.2022.839620
语言
ENGLISH
期刊等级
2区
成果收录
SCIE

作者

  • X

    Xu, Yipeng (第一作者)

    chinese acad sci · univ chinese acad sci · zhejiang canc hosp

  • P

    Pachnikova, Gabriela

查看全部 9 位作者收起作者
  • P

    Przybilla, Dorothea

  • S

    Schafer, Reinhold

  • C

    Cui, Yingying

  • Z

    Zhou, Dan

  • C

    Chen, Zihao

    southern med univ

  • Z

    Zhao, An (通讯)

    univ chinese acad sci · zhejiang canc hosp · chinese acad sci

  • K

    Keilholz, Ulrich (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417